Advances in Drug Delivery, Diagnostics, and Therapeutics for Cancer: Toward Personalized Oncology
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 20 June 2025 | Viewed by 606
Special Issue Editors
Interests: drug development; theranostics; diagnostics; therapeutics; plant extracts
Special Issues, Collections and Topics in MDPI journals
Interests: bladder cancer; breast cancer; melanoma; renal; skin cancer
Special Issues, Collections and Topics in MDPI journals
Interests: oncology and carcinogenesis; neurosciences; clinical sciences; biochemistry and cell biology; pharmacology and pharmaceutical sciences
Interests: theranostic; plant derived agents; flow cytometry; neurosurgery; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue invites contributions addressing innovative strategies in the diagnosis, treatment, and personalized management of cancer. It highlights advancements in drug delivery systems, theranostics, diagnostics, and the tumor microenvironment while emphasizing personalized oncology approaches to enhance therapeutic outcomes. Submissions may include original research, comprehensive reviews, or case studies in the following areas:
- Drug Delivery Innovations:
- Design and development of personalized, targeted drug delivery systems for cancer.
- Novel nanoparticle-based, lipid-based, or polymeric carriers tailored to patient-specific tumor profiles.
- Overcoming biological barriers to achieve selective delivery to metastatic sites.
- Therapeutics:
- Development of personalized therapies, including small molecules, biologics, and immunotherapies.
- Advances in radiation-based therapies integrated with personalized treatment strategies.
- Exploration of combination therapies targeting patient-specific metastatic pathways.
- Theranostics:
- Design of multifunctional agents that combine diagnostic and therapeutic capabilities for personalized oncology.
- Innovations in fluorescence-based or radiolabeled probes tailored to individual tumor biology.
- Real-time monitoring tools for treatment response and cancer tracking.
- Diagnostics and Biomarkers:
- Discovery of novel biomarkers for the early detection and progression monitoring of metastatic cancers.
- Development of personalized fluorescent sensors for the dynamic assessment of tumor microenvironment conditions.
- Multi-omics approaches for the identification of patient-specific predictive biomarkers and treatment customization.
- Emerging Technologies:
- Application of cutting-edge technologies in tailoring therapeutic and diagnostic approaches for cancer.
- Novel platforms for integrating personalized medicine into oncology practice.
Dr. Andreas Tzakos
Dr. Tim R. Crook
Dr. Nelofer Syed
Dr. George Alexiou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- personalized medicine
- cancer diagnostics
- cancer therapeutics
- cancer theranostics
- radiotherapeutics
- precision oncology
- targeted therapy
- immunotherapy
- molecular diagnostics
- biomarkers in cancer
- cancer genomics
- tumor microenvironment
- surgical oncology
- cancer biomarkers
- AI in cancer diagnosis
- multimodal cancer treatment
- advanced imaging in oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
